Trial Profile
A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Meibomianitis
- Focus Therapeutic Use
- Sponsors KALA BIO; Kala Pharmaceuticals
- 02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO.
- 19 Oct 2016 Status changed from active, no longer recruiting to completed.
- 26 Feb 2016 Planned End Date changed from 1 Sep 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.